Publication | Closed Access

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

Twenty-eight Day SafetyHepatologyMedicineViral HepatitisAntiviral ActivityAntiviral Drug DevelopmentHepatitis BHepatitisAntiviral TherapyPharmacotherapyTenofovir AlafenamideAntiviral DrugPharmacologyAntiviral Compound